Sonnet BioTherapeutics' Losses Mount Amid R&D Spikes

TL;DR

**Sonnet is burning cash at an alarming rate, and despite a recent capital injection, their 'going concern' warning means this stock is a high-risk gamble on future financing and clinical success.**

AI Summary

Sonnet BioTherapeutics Holdings, Inc. reported a significant increase in net loss for the nine months ended June 30, 2025, reaching $10,427,632, compared to a net loss of $4,308,639 for the same period in 2024. Collaboration revenue saw a substantial jump to $1,000,000 for the nine months ended June 30, 2025, up from $18,626 in the prior year. Operating expenses also rose considerably, with research and development increasing to $6,196,534 from $4,538,363, and general and administrative expenses climbing to $5,688,764 from $4,156,360. The company's cash position at June 30, 2025, was $321,297, a modest increase from $149,456 at September 30, 2024. Sonnet secured $10.5 million in July 2025 through convertible notes, preferred stock, warrants, and warrant exercises, which is expected to fund operations until February 2026. A business combination agreement with Hyperliquid Strategies, Inc. was entered into in July 2025, where Sonnet will become a wholly-owned subsidiary. The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows, necessitating significant additional financing.

Why It Matters

Sonnet BioTherapeutics' escalating net loss of over $10.4 million and its 'going concern' warning signal significant financial instability for investors. While the $10.5 million July financing provides a short-term lifeline, it only extends operations until February 2026, highlighting the urgent need for further capital. The pending acquisition by Hyperliquid Strategies, Inc. could offer a strategic pivot, but the competitive landscape in oncology drug development is fierce, with larger players like Roche already in collaboration. Employees face uncertainty given the financial pressures, and customers (future patients) depend on successful clinical trial progression, which is capital-intensive and risky.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' due to 'recurring losses and negative cash flows from operations since inception.' Their cash balance of $321,297 at June 30, 2025, combined with projected funding only until February 2026, provides clear evidence of high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor the Hyperliquid Strategies, Inc. acquisition closely for details on future funding and strategic direction. Avoid significant positions until a clear path to sustainable financing and clinical milestones is demonstrated.

Financial Highlights

debt To Equity

N/A

revenue

$1,000,000

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10,427,632

eps

N/A

gross Margin

N/A

cash Position

$321,297

revenue Growth

+5271%

Revenue Breakdown

Key Numbers

• $10,427,632 — Net Loss (For the nine months ended June 30, 2025, a significant increase from $4,308,639 in 2024.)
• $1,000,000 — Collaboration Revenue (For the nine months ended June 30, 2025, up from $18,626 in 2024.)
• $6,196,534 — Research and Development Expenses (For the nine months ended June 30, 2025, an increase from $4,538,363 in 2024.)
• $5,688,764 — General and Administrative Expenses (For the nine months ended June 30, 2025, an increase from $4,156,360 in 2024.)
• $321,297 — Cash (As of June 30, 2025, indicating limited liquidity.)
• $10.5 million — Capital Raised (In July 2025, expected to fund operations until February 2026.)
• 6,754,352 — Common Stock Shares Outstanding (As of August 11, 2025, reflecting recent equity issuances.)
• $3,046,479 — Total Stockholders' Deficit (As of June 30, 2025, worsening from $485,739 at September 30, 2024.)
• $5,101,826 — Total Current Liabilities (As of June 30, 2025, an increase from $3,210,196 at September 30, 2024.)
• 99 — Total Patients Exposed to SON-1010 (To date, across various clinical trials.)

Key Players & Entities

• Sonnet BioTherapeutics Holdings, Inc. (company) — Registrant and clinical stage biotechnology company
• Hyperliquid Strategies, Inc. (company) — Acquirer in a business combination agreement
• Roche (company) — Collaboration partner for clinical evaluation of SON-1010
• Alkem Laboratories Limited (company) — Licensee for SON-080 development and commercialization in India
• Sarcoma Oncology Center (company) — Collaboration partner for SON-1210 development
• Chardan Capital Markets, LLC (company) — Provider of a committed equity facility (ChEF)
• U.S. Food and Drug Administration (regulator) — Cleared IND applications for SON-1010 and SB221
• SON-1010 (product) — Lead proprietary asset, fully human version of Interleukin 12
• SON-080 (product) — Compound for Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy
• SON-1210 (product) — Lead bifunctional construct combining IL12 and IL15

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. This necessitates significant additional financing to fund operations.
• Limited Cash Reserves [high — financial]: As of June 30, 2025, the company had $321,297 in cash. While $10.5 million was raised in July 2025, this is expected to fund operations only until February 2026, indicating a continuous need for capital.
• Dependence on Future Financing [high — operational]: The company's ability to continue operations is heavily dependent on its success in raising substantial additional capital. Failure to secure necessary funding could halt operations.
• Clinical Trial Risks [medium — operational]: The company is developing therapeutics, which inherently involves risks associated with clinical trial outcomes, regulatory approvals, and market adoption. The total number of patients exposed to SON-1010 to date is 99.
• Increasing Net Loss [high — financial]: The net loss for the nine months ended June 30, 2025, was $10,427,632, a significant increase from $4,308,639 in the prior year, indicating escalating operational costs outpacing revenue growth.
• Rising Operating Expenses [medium — financial]: Both R&D expenses ($6,196,534) and G&A expenses ($5,688,764) increased substantially for the nine months ended June 30, 2025, compared to the prior year, contributing to the widening net loss.
• Worsening Stockholders' Deficit [medium — financial]: The total stockholders' deficit increased to $3,046,479 as of June 30, 2025, from $485,739 at September 30, 2024, reflecting accumulated losses.
• Business Combination Uncertainty [medium — legal]: The company entered into a business combination agreement with Hyperliquid Strategies, Inc. in July 2025. The success and implications of this combination for Sonnet's future operations and shareholder value are subject to various risks and closing conditions.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Sonnet rely heavily on innovation and securing substantial funding to advance drug candidates through clinical trials. The competitive landscape is intense, with many companies vying for market share and investor capital. Recent trends show increased collaboration and M&A activity as companies seek to de-risk development and achieve scale.

Regulatory Implications

Sonnet's operations are subject to stringent regulatory oversight by bodies like the FDA. Successful development and commercialization depend on navigating complex clinical trial requirements and obtaining marketing approvals. Any delays or failures in the regulatory process can have severe financial and operational consequences.

What Investors Should Do

1. Monitor upcoming financing activities closely, as the company's runway extends only to February 2026.
2. Evaluate the strategic rationale and potential outcomes of the business combination with Hyperliquid Strategies, Inc.
3. Assess the company's ability to achieve key clinical milestones given the increased R&D spend and the limited cash runway.
4. Analyze the terms of the recent $10.5 million financing for potential dilution and future obligations.

Key Dates

• 2025-06-30: End of Nine-Month Period — Reporting period for the 10-Q, showing increased net loss and significant revenue growth from collaborations.
• 2025-07-01: Business Combination Agreement — Sonnet entered into an agreement to be acquired by Hyperliquid Strategies, Inc., a significant strategic event.
• 2025-07-01: Capital Raise — Secured $10.5 million, crucial for extending operational runway to February 2026.
• 2025-08-11: Common Stock Shares Outstanding — Reported 6,754,352 shares outstanding, reflecting potential dilution from recent financing activities.
• 2026-02-01: Projected Funding Runway End — The $10.5 million raised in July 2025 is expected to sustain operations until this date, highlighting the urgency for further funding.

Glossary

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt, it must be disclosed. (Sonnet faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.)

Stockholders' Deficit

Occurs when a company's total liabilities exceed its total assets, resulting in a negative equity position. (Sonnet's stockholders' deficit has worsened, indicating a deteriorating equity position due to accumulated losses.)

Collaboration Revenue

Revenue generated from partnerships or agreements with other companies, often involving joint development or licensing of technology. (Sonnet experienced a significant surge in collaboration revenue, indicating progress in strategic partnerships.)

Business Combination

A merger or acquisition where two or more companies combine into a single entity. (Sonnet has entered into an agreement for a business combination with Hyperliquid Strategies, Inc., which will result in Sonnet becoming a subsidiary.)

Convertible Notes

Debt instruments that can be converted into a predetermined amount of equity (stock) of the issuing company. (Part of the $10.5 million capital raise in July 2025, indicating a financing method that could lead to future equity dilution.)

Year-Over-Year Comparison

The nine months ended June 30, 2025, show a significantly wider net loss ($10,427,632 vs. $4,308,639) compared to the same period in the prior year. While collaboration revenue saw a dramatic increase ($1,000,000 vs. $18,626), this was outpaced by substantial rises in both R&D ($6,196,534 vs. $4,538,363) and G&A expenses ($5,688,764 vs. $4,156,360). The company's cash position improved slightly but remains critically low, underscoring the ongoing going concern risks.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SONN The Nasdaq Capital M
• $20.0 million — annual aggregate revenues of less than $20.0 million (Australian) during the reimbursable pe

Filing Documents

• form10-q.htm (10-Q) — 1094KB
• ex31-1.htm (EX-31.1) — 8KB
• ex31-2.htm (EX-31.2) — 8KB
• ex32-1.htm (EX-32.1) — 5KB
• ex32-2.htm (EX-32.2) — 5KB
• 0001641172-25-023468.txt ( ) — 5049KB
• sonn-20250630.xsd (EX-101.SCH) — 39KB
• sonn-20250630_cal.xml (EX-101.CAL) — 38KB
• sonn-20250630_def.xml (EX-101.DEF) — 159KB
• sonn-20250630_lab.xml (EX-101.LAB) — 339KB
• sonn-20250630_pre.xml (EX-101.PRE) — 264KB
• form10-q_htm.xml (XML) — 720KB

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Consolidated Balance Sheets 4 Consolidated Statements of Operations 5 Consolidated Statements of Changes in Stockholders' Equity (Deficit) 6 Consolidated Statements of Cash Flows 7 Notes to Interim Consolidated Financial Statements 8 Item 2:

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3:

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 40 Item 4:

Controls and Procedures

Controls and Procedures 40 Part II Other Information 41 Item 1:

Legal Proceedings

Legal Proceedings 41 Item 1A:

Risk Factors

Risk Factors 41 Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 51 Item 3: Defaults Upon Senior Securities 51 Item 4: Mine Safety Disclosures 51 Item 5: Other Information 51 Item 6: Exhibits 52

Signatures

Signatures 53 2 SONNET BIOTHERAPEUTICS HOLDINGS, INC. INDEX TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS PART I - FINANCIAL INFORMATION Item 1: Financial Statements. Page Consolidated Balance Sheets 4 Consolidated Statements of Operations 5 Consolidated Statements of Changes in Stockholders' Equity (Deficit) 6 Consolidated Statements of Cash Flows 7 Notes to Interim Consolidated Financial Statements 8 3 Sonnet BioTherapeutics Holdings, Inc. Consolidated Balance Sheets (unaudited) June 30, 2025 September 30, 2024 Assets Current assets: Cash $ 321,297 $ 149,456 Prepaid expenses and other current assets 400,882 1,206,409 Incentive tax receivable 597,393 762,078 Total current assets 1,319,572 2,117,943 Property and equipment, net 12,854 20,523 Operating lease right-of-use asset 64,640 123,417 Deferred offering costs 171,900 15,000 Other assets 486,381 494,147 Total assets $ 2,055,347 $ 2,771,030 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 3,750,083 $ 2,183,416 Accrued expenses and other current liabilities 1,282,906 942,489 Current portion of operating lease liability 68,837 84,291 Total current liabilities 5,101,826 3,210,196 Operating lease liability, net of current portion — 46,573 Total liabilities 5,101,826 3,256,769 Commitments and contingencies (Note 4) - - Stockholders' deficit: Preferred stock, $ 0.0001 par value: 5,000,000 shares authorized; no shares issued or outstanding — — Common stock, $ 0.0001 par value: 125,000,000 shares authorized; 3,332,728 and 650,284 issued and outstanding at June 30, 2025 and September 30, 2024, respectively 333 65 Additional paid-in capital 125,061,805 117,195,181 Accumulated deficit ( 128,108,617 ) ( 117,680,985 ) Total stockholders' deficit ( 3,046,479 ) ( 485,739 ) Total liabilities and stockholders' deficit $ 2,055,347 $ 2,771,030 See accompanying n

View Full Filing

View this 10-Q filing on SEC EDGAR